Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

@article{Warnke2014CerebrospinalFJ,
  title={Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.},
  author={Clemens Warnke and Gloria von Geldern and Philipp Markwerth and Thomas Dehmel and Robert Hoepner and Ralf Gold and Michael Pawlita and Tania Kuempfel and M. M{\"a}urer and Martin Stangel and Florian Wegner and Reinhard Hohlfeld and Vera Straeten and med. Volker Limmroth and Thomas Weber and Derik Hermsen and Christoph Kleinschnitz and Hans-peter Hartung and Mike P. Wattjes and Anders Svenningson and Eugene O. Major and Tomas Olsson and Bernd C. Kieseier and Ortwin Adams},
  journal={Annals of neurology},
  year={2014},
  volume={76 6},
  pages={
          792-801
        }
}
OBJECTIVE Progressive multifocal leukoencephalopathy (PML), caused by JC virus (JCV), can occur in patients receiving natalizumab for multiple sclerosis (MS). JCV detection by quantitative polymerase chain reaction (qPCR) in cerebrospinal fluid (CSF), or brain biopsy, is required for probable or definite diagnosis of PML. However, in some patients only low levels of JCV DNA (<100 copies/ml) are present in CSF, making the diagnosis challenging. Our objective was to assess the complementary value… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod

  • Case reports in neurological medicine
  • 2016
VIEW 11 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Estimation of intrathecal IgG synthesis: simulation of the risk of underestimation

  • Annals of clinical and translational neurology
  • 2018
VIEW 1 EXCERPT
CITES RESULTS

References

Publications referenced by this paper.
SHOWING 1-10 OF 39 REFERENCES

Anti-JCV antibody index further defines PML risk in natalizumab-treated MS patients

T Plavina, M Subramanyam, G Bloomgren
  • Paper presented at: 27th Annual Meeting of the Consortium of Multiple Sclerosis Centers; May 29–Jun
  • 2013
VIEW 1 EXCERPT

Changes to anti-JCV antibody levels in a Swedish national MS cohort

  • Journal of neurology, neurosurgery, and psychiatry
  • 2013
VIEW 1 EXCERPT